183 related articles for article (PubMed ID: 25430414)
41. Increased mean platelet volume in patients with slow coronary flow.
Sen N; Basar N; Maden O; Ozcan F; Ozlu MF; Gungor O; Cagli K; Erbay AR; Balbay Y
Platelets; 2009 Feb; 20(1):23-8. PubMed ID: 19172518
[TBL] [Abstract][Full Text] [Related]
42. Thrombolysis in myocardial infarction frame count in coronary arteries without visible atherosclerosis in coronary angiography of patients with stable coronary artery disease.
Tacoy GA; Yazici GE; Kocaman SA; Ozdemir MH
Saudi Med J; 2009 Jun; 30(6):817-20. PubMed ID: 19526167
[TBL] [Abstract][Full Text] [Related]
43. Increased plasma urotensin II levels in patients with diabetes mellitus.
Totsune K; Takahashi K; Arihara Z; Sone M; Ito S; Murakami O
Clin Sci (Lond); 2003 Jan; 104(1):1-5. PubMed ID: 12519081
[TBL] [Abstract][Full Text] [Related]
44. Effect of ectasia size or the ectasia ratio on the thrombosis in myocardial infarction frame count in patients with isolated coronary artery ectasia.
Kosar F; Acikgoz N; Sahin I; Topal E; Aksoy Y; Cehreli S
Heart Vessels; 2005 Sep; 20(5):199-202. PubMed ID: 16160900
[TBL] [Abstract][Full Text] [Related]
45. Neurokinin B and urotensin II levels in pre-eclampsia.
Liu Y; Li Y; Xu X; Chen X; Chen H
J Matern Fetal Neonatal Med; 2010 Aug; 23(8):869-73. PubMed ID: 20017703
[TBL] [Abstract][Full Text] [Related]
46. Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease.
Leonard AD; Thompson JP; Hutchinson EL; Young SP; McDonald J; Swanevelder J; Lambert DG
Br J Anaesth; 2009 Apr; 102(4):477-84. PubMed ID: 19258379
[TBL] [Abstract][Full Text] [Related]
47. Assessment of coronary blood flow in non-ischemic dilated cardiomyopathy with the TIMI frame count method.
Saatçi Yaşar A; Bilen E; Yüksel IO; Ipek G; Kurt M; Ipek E; Bilge M
Anadolu Kardiyol Derg; 2010 Dec; 10(6):514-8. PubMed ID: 21047724
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of increased urotensin II levels in acute myocardial infarction.
Zhang X; Ye Y; Yang C; Gong H; Li Y; Zhang G; Yuan J; Zou Y
Discov Med; 2018 Aug; 26(141):7-20. PubMed ID: 30265851
[TBL] [Abstract][Full Text] [Related]
49. The relationship of urotensin II with insulin resistance and hs-CRP in patients having PCOS.
Yilmaz Ö; Calan O; Kume T; Calan M
Gynecol Endocrinol; 2013 Nov; 29(11):970-3. PubMed ID: 23981122
[TBL] [Abstract][Full Text] [Related]
50. Increased plasma high-sensitivity C-reactive protein and myeloperoxidase levels may predict ischemia during myocardial perfusion imaging in slow coronary flow.
Yurtdaş M; Yaylali YT; Kaya Y; Ozdemir M
Arch Med Res; 2014 Jan; 45(1):63-9. PubMed ID: 24316393
[TBL] [Abstract][Full Text] [Related]
51. Assessment of the relationship between a narrow fragmented QRS complex and coronary slow flow.
Cakmak HA; Aslan S; Gul M; Kalkan AK; Ozturk D; Celik O; Tasbulak O; Satilmisoglu MH
Cardiol J; 2015; 22(4):428-36. PubMed ID: 25588536
[TBL] [Abstract][Full Text] [Related]
52. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow.
Turhan H; Saydam GS; Erbay AR; Ayaz S; Yasar AS; Aksoy Y; Basar N; Yetkin E
Int J Cardiol; 2006 Apr; 108(2):224-30. PubMed ID: 16002164
[TBL] [Abstract][Full Text] [Related]
53. Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype.
Gruson D; Rousseau MF; Ketelslegers JM; Hermans MP
J Clin Hypertens (Greenwich); 2010 Aug; 12(8):653-60. PubMed ID: 20695946
[TBL] [Abstract][Full Text] [Related]
54. The relationship between inflammation and slow coronary flow: increased red cell distribution width and serum uric acid levels.
Kalay N; Aytekin M; Kaya MG; Ozbek K; Karayakalı M; Söğüt E; Altunkas F; Oztürk A; Koç F
Turk Kardiyol Dern Ars; 2011 Sep; 39(6):463-8. PubMed ID: 21918315
[TBL] [Abstract][Full Text] [Related]
55. Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?
Demirpence M; Guler A; Yilmaz H; Sayin A; Pekcevik Y; Turkon H; Colak A; Ari EM; Aslanipour B; Kocabas GU; Calan M
J Endocrinol Invest; 2019 Feb; 42(2):207-215. PubMed ID: 29804270
[TBL] [Abstract][Full Text] [Related]
56. Effects of slow coronary artery flow on QT interval duration and dispersion.
Atak R; Turhan H; Sezgin AT; Yetkin O; Senen K; Ileri M; Sahin O; Karabal O; Yetkin E; Kutuk E; Demirkan D
Ann Noninvasive Electrocardiol; 2003 Apr; 8(2):107-11. PubMed ID: 12848790
[TBL] [Abstract][Full Text] [Related]
57. Association between serum cystatin C levels and coronary slow flow.
Tasal A; Bacaksiz A; Ertas G; Vatankulu MA; Kul S; Sari S; Dãœz ME; Erdogan E; Sonmez O; Goktekin O
Angiology; 2014 Oct; 65(9):831-7. PubMed ID: 24101711
[TBL] [Abstract][Full Text] [Related]
58. [Plasma insulin, glucose and lipid levels, and their relations with corrected TIMI frame count in patients with slow coronary flow].
Yazici M; Demircan S; Aksakal E; Sahin M; Meriç M; Dursun I; Yüksel S; Sağkan O
Anadolu Kardiyol Derg; 2003 Sep; 3(3):222-6. PubMed ID: 12967888
[TBL] [Abstract][Full Text] [Related]
59. Impaired coronary blood flow in patients with metabolic syndrome: documented by Thrombolysis in Myocardial Infarction (TIMI) frame count method.
Turhan H; Erbay AR; Yasar AS; Bicer A; Sasmaz H; Yetkin E
Am Heart J; 2004 Nov; 148(5):789-94. PubMed ID: 15523308
[TBL] [Abstract][Full Text] [Related]
60. The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow.
Şatıroğlu Ö; Durakoğlugil ME; Çetin M; Çiçek Y; Erdoğan T; Duman H
Interv Med Appl Sci; 2016 Dec; 8(4):158-163. PubMed ID: 28180005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
